Brief: Cytotools about the results of European Phase III study of diabetic foot

bioXXmed AG

26/01/2016 08:21

Jan 26 (Reuters) - Cytotools AG  T5OG.DE : 
    * Clarifies causes that led to unexpected results of 
European Phase III study of diabetic foot 
    * Study to be repeated at short notice, after submission of 
authorization provided in EU 
 
Source text for Eikon:  ID:nEQ4KRsrMa  
Further company coverage:  T5OG.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;))